natgillin/translations-raw huggingface dataset:
• your skin becomes fragile and easily blistered, especially skin that has been frequently in the sun, and/or
• postane vaša koža krhka in se na koži hitro tvorijo mehurji, zlasti na tistih delih, ki so pogosto izpostavljeni soncu, in/ali
Follitropin alfa should not be used when an effective response cannot be obtained.
Folitropina alfa se ne sme uporabiti, če ni mogoče doseči učinkovitega odziva.
In men, FSH is needed for the production of sperm.
Pri moških je FSH potreben za nastajanje sperme.
If you are not ovulating, have no periods and have been diagnosed with very low levels of FSH and LH hormones
Če nimate ovulacije, nimate menstruacije in imate diagnozo zelo nizkih ravni hormonov FSH in LH
Your doctor or nurse will show you how to inject the medicine.
Vaš zdravnik ali medicinska sestra vam bosta pokazala, kako se injicira zdravilo.
Therefore, patients should be followed for at least 2 weeks after hCG administration.
Zato je treba bolnice spremljati najmanj 2 tedna po dajanju hCG.
In women with recent or ongoing thromboembolic disease or women with generally recognised risk factors for thromboembolic events, such as personal or family history, treatment with gonadotropins may further increase the risk for aggravation or occurrence of such events.
Pri ženskah z nedavnimi ali potekajočimi trombemboličnimi boleznimi ali pri ženskah s splošno znanimi dejavniki tveganja za trombembolične dogodke, kot so osebna ali družinska anamneza, lahko zdravljenje z gonadotropini še poveča tveganje za poslabšanje ali pojav teh dogodkov.
Empty cartridges must not be refilled.
Praznih vložkov ni dovoljeno ponovno napolniti.
This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called “metabolic acidosis”).
Večje količine benzilalkohola se namreč lahko kopičijo v vašem telesu in povzročajo neželene učinke (imenovane »metabolična acidoza«).
The very first injection of this medicine should only be given in the presence of a doctor or nurse.
Prvo injekcijo tega zdravila si morate dati v prisotnosti zdravnika ali medicinske sestre.
Each cartridge must be used by a single patient only.
Vsak vložek se lahko uporablja samo pri enem bolniku.
• If you have irregular periods, start using this medicine within the first 7 days of your menstrual cycle.
• Če imate neredne menstruacije, začnite uporabljati to zdravilo v roku prvih 7 dni vašega menstrualnega ciklusa.
As the multidose cartridge is intended for several injections, clear instructions should be provided to the patients to avoid misuse of the medicine.
Ker je večodmerni vložek namenjen dajanju več injekcij, mora dobiti bolnik jasna navodila za uporabo, v izogib napačni uporabi zdravila.
If you do not have periods, you can start using the medicine on any convenient day.
Če nimate menstruacij, lahko začnete zdravilo uporabljati kateri koli dan, kot vam ustreza.
Complication of severe OHSS
redki zaplet resnega OHSS
Data on a limited number of exposed pregnancies (less than 300 pregnancy outcomes) indicate no malformative or foeto/neonatal toxicity of follitropin alfa.
Podatki omejenega števila izpostavljenih nosečnosti (manj kot 300 izidov nosečnosti) ne kažejo na malformacijsko ali feto/neonatalno toksičnost folitropina alfa.
If you need to develop several eggs for collection prior to any assisted reproductive technology
Če želite, da se razvije več jajčec za odvzem pred tehniko asistirane reprodukcije
Therefore, it is considered appropriate to give a lower total dose of follitropin alfa than generally used for urinary FSH, not only in order to optimise follicular development but also to minimise the risk of unwanted ovarian hyperstimulation (see section 5.1).
Zato je primerno, da predpišemo nižji skupni odmerek folitropina alfa kot se običajno uporablja za urinarni FSH, ne samo za optimiranje razvoja foliklov, ampak tudi zato, da čim bolj zmanjšamo tveganje za neželeno hiperstimulacijo jajčnikov (glejte poglavje 5.1).
For accurate interpretation of the indices of follicle development and maturation, the physician should be experienced in the interpretation of the relevant tests.
Za pravilno interpretacijo kazalcev folikularnega razvoja in dozorevanja mora imeti zdravnik izkušnje na področju interpretacije tovrstnih testov.
If you experience the above symptoms your doctor may recommend that you stop treatment.
Če se pojavijo zgoraj navedeni simptomi, vam lahko zdravnik priporoča, da prenehate z zdravljenjem.
• you gain any weight rapidly,
• hitro pridobite telesno maso,
This could cause chest pain, breathlessness, stroke or heart attack [see also section 2 under “Blood clotting problems (thromboembolic events)”].
Povzročijo lahko bolečino v prsih, zasoplost, kap ali srčni napad [glejte tudi poglavje 2 "Težave s strjevanjem krvi (trombembolični dogodki)"].
The maximal daily dose is usually not higher than 225 IU FSH.
Maksimalni dnevni odmerek običajno ni večji kot 225 i.e. FSH.
Clinical assessment of follitropin alfa indicates that its daily doses, regimens of administration and treatment monitoring procedures should not be different from those currently used for urinary FSH-containing medicinal products.
Klinična ocena folitropina alfa kaže, da njegovi dnevni odmerki, režim uporabe in postopki nadzorovanja zdravljenja ne bi smeli biti drugačni od tistih, ki se trenutno uporabljajo za zdravila z urinarnim FSH.
Pregnancy and breast-feeding You should not use this medicine if you are pregnant or breast-feeding.
Nosečnost in dojenje Ne uporabljajte tega zdravila, če ste noseči ali če dojite.
The effects of an overdose of follitropin alfa are unknown, nevertheless, there is a possibility that OHSS may occur (see section 4.4).
Učinki prevelikega odmerka folitropina alfa niso znani, vendar pa obstaja možnost, da se pojavi OHSS (glejte poglavje 4.4).
Deterioration or a first appearance of this condition may require cessation of treatment.
Poslabšanje ali prvi pojav porfirije lahko zahteva prekinitev zdravljenja.
In particular, patients should be evaluated for hypothyroidism, adrenocortical deficiency, hyperprolactinemia and appropriate specific treatment given.
Bolnike je treba še posebej pregledati na hipotiroidizem, adrenokortikalno insuficienco, hiperprolaktinemijo ter jih ustrezno specifično zdraviti.
• Swelling of the veins above and behind the testicles (a varicocele)
• oteklost žil nad testisi in za njimi (varikokela)
Pharmacotherapeutic group: Sex hormones and modulators of the genital systems, gonadotropins, ATC code: G03GA05.
Farmakoterapevtska skupina: Spolni hormoni in zdravila za uravnavanje delovanja spolovil, gonadotropni hormoni, oznaka ATC: G03GA05.
Your doctor or nurse will give you instructions on how to do this and you can also find instructions in the separate instructions for use of the pen.
Vaš zdravnik ali medicinska sestra vas bosta o tem poučila, napotke pa najdete tudi v ločenem navodilu za uporabo injekcijskega peresnika.
Gonadotropin therapy requires a certain time commitment by physicians and supportive health professionals, as well as the availability of appropriate monitoring facilities.
Zdravljenje z gonadotropinom zahteva od zdravnika in ostalega zdravstvenega osebja določen čas, kakor tudi razpoložljivost ustrezne opreme za nadzorovanje zdravljenja.
4.7 Effects on ability to drive and use machines Ovaleap has no or negligible influence on the ability to drive and use machines.
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Zdravilo Ovaleap nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Adherence to recommended follitropin alfa dose and regimen of administration can minimise the risk of ovarian hyperstimulation (see sections 4.2 and 4.8).
Upoštevanje priporočenega odmerka folitropina alfa in režima uporabe lahko zmanjšata tveganje hiperstimulacije jajčnikov (glejte poglavji 4.2 in 4.8).
Mild or moderate OHSS has been commonly reported and should be considered as an intrinsic risk of the stimulation procedure.
Pogosto so poročali o blagem ali zmernem OHSS, ki ga je treba obravnavati kot tveganje, značilno za postopek stimulacije.
• The usual dose of this medicine is 150 IU together with hCG.
• Običajni odmerek tega zdravila je 150 i.e. skupaj s hCG.
Table 3: Results of study GF 8407 (randomised parallel group study comparing efficacy and safety of follitropin alfa with urinary FSH in ART)
Preglednica 3: Rezultati študije GF 8407 (randomizirana študija z vzporednima skupinama, pri kateri so primerjali učinkovitost in varnost folitropina alfa z urinarnim FSH pri ART) folitropin alfa (n = 130)
If you have ever had blood clots in your leg or lung, or a heart attack or stroke, or if your family have experienced these, inform your doctor.
Težave s strjevanjem krvi (trombembolični dogodki) Če ste kadar koli imeli krvne strdke v nogah ali v pljučih, srčni napad ali kap, ali če se je to zgodilo kakemu družinskemu članu, obvestite svojega zdravnika.
• you feel sick or are vomiting,
• vam je slabo ali bruhate,
Follitropin alfa should be given at a dose of 150 IU three times a week, concomitantly with hCG, for a minimum of 4 months.
Folitropin alfa se mora dajati v odmerku 150 i.e., trikrat na teden, sočasno s hCG, najmanj 4 mesece.
This could be related to multiple pregnancies or to parent characteristics such as maternal age and sperm characteristics.
To je lahko povezano z večplodno nosečnostjo ali lastnostmi staršev kot so materina starost in lastnosti sperme.
A commonly used regimen commences at 75-150 IU FSH daily and is increased preferably by 37.5 or 75 IU at 7 or preferably 14 day intervals if necessary, to obtain an adequate, but not excessive, response.
Režim, ki se običajno uporablja, se prične z odmerkom 75-150 i.e. FSH na dan, in se ga, če je potrebno, povečuje za 37,5 ali 75 i.e. v 7 ali najbolje v 14 dnevnih intervalih, za doseganje zadostnega, a ne pretiranega odziva.
If severe OHSS occurs, it is recommended that gonadotropin treatment be stopped if still ongoing and that the patient be hospitalised and appropriate therapy be started.
Če se pojavi hud OHSS, je priporočljivo zdravljenje z gonadotropinom ukiniti, v kolikor še traja, in bolnico sprejeti v bolnišnico in začeti ustrezno zdravljenje OHSS.
You might have a higher risk of these problems occurring or becoming worse with Ovaleap treatment.
Morda je pri vas večje tveganje, da se te težave pri zdravljenju z zdravilom Ovaleap pojavijo ali poslabšajo.
The maximum daily dose is 450 IU.
Največji dnevni odmerek je 450 i.e..
PHARMACEUTICAL FORM Solution for injection (injection).
FARMACEVTSKA OBLIKA Raztopina za injiciranje (injekcija).
This medicine contains the active substance follitropin alfa, which is almost identical to a natural hormone produced by your body called “follicle-stimulating hormone” (FSH).
To zdravilo vsebuje učinkovino folitropin alfa, ki je skoraj identična naravnemu hormonu, ki nastaja v telesu, imenovanim "folikle stimulirajoči hormon" (FSH).
• Hypersensitivity to the active substance follitropin alfa, FSH or to any of the excipients listed in section 6.1;
• preobčutljivost na učinkovino folitropin alfa, FSH ali katero koli pomožno snov, navedeno v poglavju 6.1
The lowest effective dose in relation to the treatment objective should be used in both men and women.
Tako pri moških kot pri ženskah se mora uporabiti najmanjši še učinkoviti odmerek glede na namen zdravljenja.
In a commonly used protocol, follitropin alfa is started approximately 2 weeks after the start of agonist treatment, both being continued until adequate follicular development is achieved.
Po protokolu, ki se splošno uporablja, se zdravljenje s folitropinom alfa začne približno 2 tedna po začetku zdravljenja z agonistom in se nadaljuje z dajanjem obeh zdravil, dokler ni dosežen zadosten folikularni razvoj.
Table 2: Adverse reactions in men System organ class
Preglednica 2: Neželeni učinki pri moških Organski sistem
Semen analysis is recommended 4 to 6 months after the beginning of treatment as part of the assessment of the response.
Kot del ocenjevanja odziva se priporoča analiza semenske tekočine 4 do 6 mesecev po začetku zdravljenja.
Women with anovulation (including polycystic ovarian syndrome) Follitropin alfa may be given as a course of daily injections.
Ženske z anovulacijo (vključno s sindromom policističnih jajčnikov) Folitropin alfa se lahko daje kot zaporedje dnevnih injekcij.
• You will use these two medicines each day for up to 5 weeks.
• Ti dve zdravili boste naslednjih pet tednov uporabljali vsak dan.
• When you get the desired response, you will be given hCG or “recombinant hCG” (r-hCG, an hCG made in a laboratory by a special DNA technique).
• Ko boste dosegli želeni odziv, boste prejeli hCG ali "rekombinantni hCG" (r-hCG, v laboratoriju izdelan hCG s posebno tehnologijo DNA).
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 27 September 2013.
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 27. september 2013 Datum zadnjega podaljšanja: 16. maja 2018
If your doctor decides to try Ovaleap treatment, they may monitor it by asking you to provide semen for analysis 4 to 6 months after starting treatment.
Če se zdravnik odloči, da vas bo poskusil zdraviti z zdravilom Ovaleap, vas bo za spremljanje vašega zdravljenja 4 do 6 mesecev po začetku zdravljenja morda prosil za vzorce sperme za analizo.
Do not attempt to self-administer this medicine without this training by your doctor or nurse.
Tega zdravila si ne poskušajte injicirati sami, če vas o tem nista ustrezno poučila vaš zdravnik ali medicinska sestra.
Follitropin alfa is a potent gonadotropic substance capable of causing mild to severe adverse reactions and should only be used by physicians who are thoroughly familiar with infertility problems and their management.
Folitropin alfa je močna gonadotropna učinkovina, ki lahko povzroči blage do hude neželene učinke in jo zato smejo uporabljati samo zdravniki, ki dobro poznajo težave z neplodnostjo in njihovo obvladovanje.
Driving and using machines This medicine does not affect your ability to drive and use machines.
Vpliv na sposobnost upravljanja vozil in strojev To zdravilo ne vpliva na sposobnost vožnje ali upravljanja strojev.
• The usual starting dose of this medicine is 150 to 225 IU each day, from day 2 or 3 of your menstrual cycle.
• Običajni začetni odmerek tega zdravila je 150 do 225 i.e. vsak dan, od 2. ali 3. dneva vašega menstrualnega ciklusa.
• The maximum daily dose of this medicine is usually not higher than 225 IU.
• Največji dnevni odmerek tega zdravila običajno ne presega 225 i.e..
Patients with porphyria or a family history of porphyria should be closely monitored during treatment with follitropin alfa.
Bolnike s porfirijo ali s porfirijo v družinski anamnezi moramo med zdravljenjem s folitropinom alfa skrbno nadzorovati.
Treatment with follitropin alfa should be initiated under the supervision of a physician experienced in the treatment of fertility disorders.
Zdravljenje s folitropinom alfa se mora pričeti pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem motenj plodnosti.
Independent risk factors for developing OHSS include polycystic ovarian syndrome high absolute or rapidly rising serum oestradiol levels (e.g. > 900 pg/mL or > 3,300 pmol/L in anovulation; > 3,000 pg/mL or > 11,000 pmol/L in ART) and large number of developing ovarian follicles (e.g. > 3 follicles of ≥ 14 mm in diameter in anovulation; ≥ 20 follicles of ≥ 12 mm in diameter in ART).
Neodvisni dejavniki tveganja za razvoj OHSS vključujejo sindrom policističnih jajčnikov, visoke absolutne ali hitro naraščajoče ravni estradiola v serumu (npr. > 900 pg/ml ali > 3.300 pmol/l v anovulaciji; > 3.000 pg/ml ali > 11.000 pmol/l v ART) in veliko število razvijajočih se ovarijskih foliklov (npr. > 3 folikli s premerom ≥ 14 mm v anovulaciji; ≥ 20 foliklov premera ≥ 12 mm v ART).
For instructions on the administration with the Ovaleap Pen, see section 6.6.
Za navodilo o dajanju zdravila z injekcijskim peresnikom Ovaleap Pen glejte poglavje 6.6.
The instructions for use of the pen must be followed carefully.
Navodila za uporabo injekcijskega peresnika je treba natančno upoštevati.
In women, the most important effect resulting from parenteral administration of FSH is the development of mature Graafian follicles.
Pri ženskah je najpomembnejši učinek po parenteralni uporabi FSH razvoj zrelih Graafovih foliklov.
If you experience the above symptoms your doctor might ask you to stop using this medicine (see also section 4 under “Serious side effects in women").
Če se pojavijo zgornji simptomi, vas bo morda zdravnik prosil, da zdravilo prenehate uporabljati (glejte tudi poglavje 4 "Neželeni učinki pri ženskah").
When being conceived by assisted reproductive technology, a baby may have a slightly higher risk of birth defects than after natural conception.
Pri zanositvi s tehnikami asistirane reprodukcije ima otrok lahko nekoliko večje tveganje za prirojene napake kot pri naravni zanositvi.
If you are not sure, talk to your doctor or pharmacist before using this medicine.
Če niste prepričani, se pred začetkom jemanja tega zdravila posvetujte z zdravnikom ali farmacevtom.
Ovaleap is indicated for use in infertility (see section 4.1).
Zdravilo Ovaleap je indicirano za uporabo pri neplodnosti (glejte poglavje 4.1).
• gynaecological haemorrhages of unknown aetiology;
• ginekološka krvavitev neznane etiologije
When using this medicine, you have a higher risk of being pregnant with more than one child (i.e. “multiple pregnancy”, typically twins) than if you conceived naturally.
Pri uporabi tega zdravila je tveganje za nosečnost z več plodi večja (npr. "večplodna nosečnost", običajno dvojčki) kot pri naravni zanositvi.
In clinical trials these patients were defined by an endogenous serum LH level < 1.2 IU/L.
V kliničnih študijah so bile te bolnice določene na podlagi ravni endogenega LH v serumu < 1,2 i.e./l.
Before starting treatment, the couple's infertility should be assessed as appropriate and putative contraindications for pregnancy evaluated.
Pred začetkom zdravljenja se mora primerno oceniti neplodnost para ter ovrednotiti domnevne kontraindikacije za nosečnost.
If you notice any of the above-listed side effects you should immediately contact your doctor who may ask you to stop using Ovaleap.
Če opazite katerega koli od zgoraj navedenih neželenih učinkov, se takoj posvetujte z zdravnikom, ki vam bo morda svetoval da prenehate uporabljati zdravilo Ovaleap.
• OHSS may become severe with clearly enlarged ovaries, decreased urine production, weight gain, difficulty in breathing and/or possible fluid accumulation in your stomach or chest.
• OHSS lahko postane resen z izrazito povečanimi jajčniki, zmanjšanim nastajanjem urina, s pridobivanjem telesne mase, težavami dihanja in/ali morebitnim nabiranjem tekočine v trebuhu ali prsnem košu.
There is no indication for use of Ovaleap during pregnancy.
Za uporabo zdravila Ovaleap med nosečnostjo ni indikacij.
Therefore, if signs of ovarian hyperstimulation occur such as serum oestradiol level > 5,500 pg/mL or > 20,200 pmol/L and/or ≥ 40 follicles in total, it is recommended that hCG be withheld and the patient be advised to refrain from coitus or to use barrier contraceptive methods for at least 4 days.
Zato je v primeru pojava znakov hiperstimulacije jajčnikov, kot so ravni estradiola v serumu > 5.500 pg/ml ali > 20.200 pmol/l in/ali skupno ≥40 foliklov, priporočljivo, da se opusti dajanje hCG in se bolnici svetuje, da se vzdrži spolnih odnosov ali uporablja mehanska kontracepcijska sredstva najmanj 4 dni.
In women, FSH is needed for the growth and development of the sacs (follicles) in the ovaries that contain the egg cells.
Pri ženskah je FSH potreben za rast in razvoj jajčnih mehurčkov (foliklov) v jajčnikih.
In women, safe and effective use of follitropin alfa calls for monitoring of ovarian response with ultrasound, alone or preferably in combination with measurement of serum oestradiol levels, on a regular basis.
Pri ženskah je za varno in učinkovito uporabo folitropina alfa potrebno redno nadzorovanje odziva jajčnikov z ultrazvokom ali še bolje z ultrazvokom v kombinaciji z merjenjem serumskih ravni estradiola.
Safety, efficacy and pharmacokinetics of follitropin alfa in patients with renal or hepatic impairment have not been established.
Varnost, učinkovitost in farmakokinetika folitropina alfa pri bolnikih z ledvično ali jetrno okvaro niso bili dokazani.
• in combination with a medicine called “lutropin alfa” (a version of another gonadotropin, “luteinising hormone” or LH) to help ovulation in women that are not ovulating because their body is producing too little FSH and LH.
• v kombinaciji z drugim zdravilom, ki se imenuje "lutropin alfa" (različica drugega gonadotropina, "luteinizirajočega hormona" ali LH) za pomoč pri ovulaciji pri ženskah, ki nimajo ovulacije, ker njihovo telo proizvaja premalo FSH in LH.
Before the treatment is started you and your partner's fertility should be evaluated by a doctor experienced in treating fertility disorders.
Pred začetkom zdravljenja mora plodnost vas in vaše partnerke/partnerja oceniti zdravnik z izkušnjami pri zdravljenju motenj plodnosti.
• fibroid tumours of the uterus incompatible with pregnancy;
• fibroidni tumorji maternice, ki niso združljivi z nosečnostjo
Marketing Authorisation Holder Theramex Ireland Limited 3rd Floor, Kilmore House,
Imetnik dovoljenja za promet z zdravilom Theramex Ireland Limited 3rd Floor, Kilmore House,
Exacerbation or aggravation of asthma
• poslabšanje astme
If a patient fails to respond adequately after 4 weeks of treatment, that cycle should be abandoned and the patient should undergo further evaluation after which she may recommence treatment at a higher starting dose than in the abandoned cycle.
Če pri bolnici ni zadovoljivega odziva na zdravljenje po 4 tednih, se mora ta ciklus zdravljenja opustiti, bolnico ponovno oceniti, nato pa bo morda morala ponovno zdravljenje začeti z večjim začetnim odmerkom kot v opuščenem ciklusu.
Then Ovaleap is given approximately 2 weeks after the start of agonist treatment.
Nato se približno 2 tedna po začetku zdravljenja z agonistom daje zdravilo Ovaleap.
Merckle GmbH Graf-Arco-Straße 3 89079 Ulm, Germany
Merckle GmbH Graf-Arco-Straße 3 89079 Ulm, Nemčija
Clinical evaluation may reveal hypovolaemia, haemoconcentration, electrolyte imbalances, ascites, haemoperitoneum, pleural effusions, hydrothorax, or acute pulmonary distress.
Klinična ocena lahko razkrije hipovolemijo, hemokoncentracijo, elektrolitsko neravnovesje, ascites, hemoperitonej, plevralni izliv, hidrotoraks ali akutno respiratorno stisko.
Do not use Ovaleap:
Ne uporabljajte zdravila Ovaleap:
If you are not ovulating and if the recommended dose and timing are followed, the occurrence of OHSS is less likely.
Če nimate ovulacije in upoštevate priporočeni odmerek in čas, je manj verjetno, da bi se pojavil sindrom hiperstimulacije jajčnikov.
• Your dose of this medicine may be increased every 7 or every 14 days by 37.5 to 75 IU, until you get the desired response.
• Vaš odmerek tega zdravila se lahko poveča vsakih 7 ali 14 dni za 37,5 do 75 i.e., dokler ne boste dosegli želenega odziva.
If you forget to use Ovaleap
Če ste pozabili uporabiti zdravilo Ovaleap
Luteal phase support may be considered since lack of substances with luteotropic activity (LH/hCG) after ovulation may lead to premature failure of the corpus luteum.
Podpora lutealne faze je morda potrebna, ker lahko pomanjkanje snovi z luteotropnim učinkom (LH/hCG) po ovulaciji vodi do prezgodnje odpovedi rumenega telesca.
When undergoing assisted reproductive technology the risk of having a multiple pregnancy is related to your age, the quality and number of fertilised eggs or embryos placed inside you.
Pri uporabi tehnik asistirane reprodukcije je tveganje za večplodno nosečnost povezano z vašo starostjo in kakovostjo ter številom prenesenih oplojenih jajčec ali embrijev.
Comparative clinical studies have shown that on average patients require a lower cumulative dose and shorter treatment duration with follitropin alfa compared with urinary FSH.
Primerjalne klinične študije so pokazale, da potrebuje bolnik v povprečju nižji skupni odmerek in krajše trajanje zdravljenja s folitropinom alfa kot z urinarnim FSH.